Table 4.
Demographic birth data and neonatal abstinence syndrome (NAS) parameters
| Standard protocol (n=77)
|
Clinical trial (n=37)
|
Significance*
|
|||||
|---|---|---|---|---|---|---|---|
| Meth (n=51) | Bup (n=26) | Meth (n=19) | Bup (n=18) | pTR | pOM | pIA | |
|
|
|
||||||
| Mean (SD) | Mean (SD) | Mean (SD) | Mean (SD) | ||||
| GA at delivery (weeks) | 38.59 (1.92) | 39.65 (1.62) | 38.37 (2.17) | 39.72 (2.37) | 0.851 | 0.003 | 0.722 |
| Birth weight (g) | 2729.06 (510.48) | 3151.08 (541.64) | 2861.58 (402.59) | 2966.72 (504.16) | 0.800 | 0.011 | 0.124 |
| Body length (cm) | 48.26 (3.30) | 50.23 (3.28) | 48.66 (2.76) | 49.11 (2.65) | 0.572 | 0.059 | 0.236 |
| Head circumference (cm) | 32.93 (1.72) | 33.56 (1.75) | 33.61 (1.70) | 33.61 (1.97) | 0.319 | 0.383 | 0.392 |
| Total morphine dose (mg) | 21.61 (26.64) | 4.30 (7.30) | 5.18 (6.94) | 2.02 (1.71) | 0.014 | 0.008 | 0.061 |
| NAS treatment (days) | 21.25 (21.22) | 6.62 (8.07) | 9.53 (9.14) | 7.33 (4.46) | 0.079 | 0.008 | 0.048 |
| Length of stay (days) | 29.36 (17.94) | 13.92 (7.33) | 16.74 (6.78) | 13.67 (2.63) | 0.015 | 0.001 | 0.019 |
Meth, methadone; Bup, buprenorphine; SD, standard deviation; GA, gestational age.
This table shows routine birth data as well as NAS characteristics for the whole study sample (N=114), listed according to treatment approach (standard protocol versus clinical trial) and opioid medication the mothers received throughout pregnancy (buprenorphine versus methadone).
Significance of comparisons (p-values) was calculated in 3 ways: pTR indicates the significance regarding treatment approach (standard protocol versus clinical trial), pOM indicates the significance regarding opioid medication (buprenorphine versus methadone) and pIA indicates the significance taking into account the interaction between treatment approach and opioid medication.